Tumors with Ret Activation

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2022-06-02
Clinical Trial Update: A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation [Phase 2]
Phase 2 study of selpercatinib (Retevmo) in adults with advanced RET-altered solid tumors, including RET fusion–positive cancers and medulla…